BEPOTASTINE Pharmacologic Class Indexing
- Class set ID
- 2e82cea8-93c1-4da2-b61d-e3e1b6ec9bb4
- Version
- 2
- Effective date
- 20180813
- Type
- Indexing - Pharmacologic Class
Mapped DailyMed Labels#
Label, Manufacturer, Effective table| Label | Manufacturer | Effective | SPL version |
|---|
| These highlights do not include all the information needed to use BEPOTASTINE BESILATE OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for BEPOTASTINE BESILATE OPHTHALMIC SOLUTION BEPOTASTINE BESILATE ophthalmic solution 1.5%, for topical ophthalmic use Initial U.S. Approval:2009 | Somerset Therapeutics, LLC | Somerset Therapeutics Private Limited | 20241010 | 4 |
| These highlights do not include all the information needed to use Bepotastine Besilate Ophthalmic Solution safely and effectively. See full prescribing information for Bepotastine Besilate Ophthalmic Solution. Bepotastine Besilate Ophthalmic Solution, for topical ophthalmic use Initial U.S. Approval: 2009 | Bausch & Lomb Americas Inc. | Bausch & Lomb Incorporated | 20240820 | 4 |
| These highlights do not include all the information needed to use BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5% safely and effectively. See full prescribing information for BEPOTASTINE BESILATE OPHTHALMIC SOLUTION. BEPOTASTINE Besilate Ophthalmic Solution 1.5% for topical ophthalmic use Initial U.S. Approval: 2009 | Alembic Pharmaceuticals Limited | Alembic Pharmaceuticals Limited (F3) | 20230721 | 1 |
| These highlights do not include all the information needed to use BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5% safely and effectively. See full prescribing information for BEPOTASTINE BESILATE OPHTHALMIC SOLUTION. BEPOTASTINE Besilate Ophthalmic Solution 1.5% for topical ophthalmic use Initial U.S. Approval: 2009 | Alembic Pharmaceuticals Inc. | Alembic Pharmaceuticals Limited (F3) | 20230721 | 4 |
| These highlights do not include all the information needed to use BEPREVE safely and effectively. See full prescribing information for BEPREVE. BEPREVE ® (bepotastine besilate ophthalmic solution), for topical ophthalmic use Initial U.S. Approval: 2009 | Bausch & Lomb Incorporated | 20220831 | 14 |
| These highlights do not include all the information needed to use BEPOTASTINE BESILATE OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for BEPOTASTINE BESILATE OPHTHALMIC SOLUTION. BEPOTASTINE BESILATE OPHTHALMIC SOLUTION, 1.5%, for topical ophthalmic use Initial U.S. Approval: 2009 | Bausch & Lomb Incorporated | 20201231 | 1 |
| These highlights do not include all the information needed to use BEPOTASTINE BESILATE OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for BEPOTASTINE BESILATE OPHTHALMIC SOLUTION. BEPOTASTINE BESILATE ophthalmic solution, for topical application in the eye Initial U.S. Approval: 2009 | Mylan Pharmaceuticals Inc. | 20180320 | 4 |
| These highlights do not include all the information needed to use BEPREVE™ (bepotastine besilate ophthalmic solution) 1.5% safely and effectively. See full prescribing information for BEPREVE™. BEPREVE™ (bepotastine besilate ophthalmic solution) 1.5% Initial U.S. Approval: 2009 | Physicians Total Care, Inc. | 20090801 | 1 |